- Home >
- Life Sciences >
- Pharmaceutical >
- Therapy >
Worldwide Psychotherapeutic Drug Market
Worldwide Psychotherapeutic Drug Market
- Report price : $ 500
- Publication date : September 2006
- Length : 11 pages
Worldwide Psychotherapeutic Drug Market
The ``Sector Snapshot`` is designed to provide a high-level overview of a particular market sector, including key players, sales data and emerging trends. This sector snapshot covers the global market for psychotherapeutic drugs, of which the majority of sales for the central nervous system were in the seven major world markets, i.e., the U.S., France, Germany, Italy, Spain, the U.K. and Japan. This snapshot also details the key drug types, general classifications of psychotherapeutic drugs, the competitive landscape, market opportunities, and common psychotherapeutic drugs.
RELATED REPORTS
Disease and Therapy Review: Major Depressive Disorder
- $ 900
- January 2007
- 12 pages
The Major Depressive Disorder Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatments, including SSRIs and atypical antidepressants, tricyclic antidepressants, monoamine oxidase inhibi ...
Industries : Therapy | Countries : Mexico, Canada, USA, China, Japan, Germany, Spain, France, United Kingdom
Disease and Therapy Review: Parkinson's Disease
- $ 900
- August 2006
- 8 pages
The Parkinson's Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, and an overview of treatments, including Levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors, and surgical options. General sales information is included fo ...
Industries : Therapy | Countries : USA, China, Japan, India, Spain, Italy, United Kingdom
Disease and Therapy Review: Insomnia
- $ 900
- January 2007
- 9 pages
The Insomnia Disease and Therapy Review provides prevalence numbers and percentages for major countries worldwide, information on diagnostic criteria, and an overview of treatments. Dosing information and treatment costs are provided for Rozerem, Sonata, Lunesta, and Ambien. General information is i ...
Industries : Therapy | Countries : Canada, USA, Japan, Germany, France
Disease and Therapy Review: Cervical Cancer
- $ 900
- February 2007
- 9 pages
The Cervical Cancer Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, 5-year survival rates by stage, and information on diagnosis and staging. An overview of treatments for prevention, emergency measures, and specific measures such ...
Industries : Therapy | Countries : Mexico, Canada, USA, China, Japan, India, Germany, Spain, France, Italy, United Kingdom
Stakeholder Opinions: Esophageal Cancer Treatment paradigms need revolution not evolution
- $ 3 800
- March 2007
- 133 pages
IntroductionGlobally, esophageal cancer is the ninth most common tumor type and seventh leading cause of cancer-related death, however, its incidence fluctuates widely depending on geographical area. While relatively uncommon in Western countries, 50% of patients still present with locally advanced ...
Industries : Therapy | Countries : USA, Japan, United Kingdom
Cancer Therapeutics:The Worldwide Market , 2nd Editon
- $ 3 995
- February 2007
- 545 pages
Few pharmaceutical markets will see the dramatic change that will occur in cancer therapeutics over the next four years. More than $8 billion dollars worth of new products are expected in the next four years, impacting the treatment of cancer in ways that product managers, strategic planners, busine ...
Multiple Sclerosis World Market Outlook to 2011
- $ 2 995
- June 2007
- 110 pages
Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS that causes significant disability in young adults. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved qu ...
Commercial Insight: Depression - Atypical lifecycle management strategy rejuvenates depression market
- $ 15 200
- June 2007
- 142 pages
IntroductionNovel pipeline drugs, lifecycle management of the current branded antidepressants, and development of atypical antipsychotics for depression are set to grow the depression market through to 2010 when it will peak at $14.6 billion. Thereafter, however, generic incursion of the atypical an ...
Commercial Insight: Insomnia Strong brand identity critical to differentiation in an increasingly crowded market
- $ 15 200
- June 2007
- 116 pages
IntroductionAmbien has remained the clear leader in the insomnia market for over a decade, with 2006 sales of over $2.3 billion across the seven major markets. The success of Ambien is attributable to a favorable side-effect profile and half-life. However, due to recent patent expiries in the US and ...
Industries : Therapy | Countries : USA, China, Japan, India, Spain, France
Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment
- $ 15 200
- June 2007
- 114 pages
IntroductionThe dynamic MS market continues to grow unabated; seven major market revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer acetate), and the recent relaunch of Tysabri; the first launch of ...
Industries : Therapy | Countries : USA, Japan, Germany, France, Ireland, Italy, United Kingdom
Related industries
reportlinker.com © Copyright 2009. All rights reserved